A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508426-10-00

Acronym

64007957MMY1008

Enrollment

Registered

2024-06-03

Start date

2024-06-03

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026